FR2721214B1 - Formulations d'analogues de l'insuline. - Google Patents

Formulations d'analogues de l'insuline.

Info

Publication number
FR2721214B1
FR2721214B1 FR9507094A FR9507094A FR2721214B1 FR 2721214 B1 FR2721214 B1 FR 2721214B1 FR 9507094 A FR9507094 A FR 9507094A FR 9507094 A FR9507094 A FR 9507094A FR 2721214 B1 FR2721214 B1 FR 2721214B1
Authority
FR
France
Prior art keywords
insulin analog
analog formulations
formulations
insulin
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR9507094A
Other languages
English (en)
Other versions
FR2721214A1 (fr
Inventor
Diane Lee Bakaysa
David Nettleship Brems
Bruce Hill Frank
Henry Acken Havel
Allen Howard Pekar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2721214(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of FR2721214A1 publication Critical patent/FR2721214A1/fr
Application granted granted Critical
Publication of FR2721214B1 publication Critical patent/FR2721214B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
FR9507094A 1994-06-16 1995-06-14 Formulations d'analogues de l'insuline. Expired - Lifetime FR2721214B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (2)

Publication Number Publication Date
FR2721214A1 FR2721214A1 (fr) 1995-12-22
FR2721214B1 true FR2721214B1 (fr) 1997-09-26

Family

ID=22989969

Family Applications (2)

Application Number Title Priority Date Filing Date
FR9507094A Expired - Lifetime FR2721214B1 (fr) 1994-06-16 1995-06-14 Formulations d'analogues de l'insuline.
FR9700156A Expired - Lifetime FR2741078B1 (fr) 1994-06-16 1997-01-09 Formulations d'analogues de l'insuline

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR9700156A Expired - Lifetime FR2741078B1 (fr) 1994-06-16 1997-01-09 Formulations d'analogues de l'insuline

Country Status (39)

Country Link
US (1) US5474978A (fr)
JP (2) JP3171541B2 (fr)
KR (1) KR100382326B1 (fr)
CN (1) CN1105576C (fr)
AT (1) AT408720B (fr)
BE (1) BE1009408A5 (fr)
BR (1) BR9502795A (fr)
CA (1) CA2151560C (fr)
CH (2) CH689935A5 (fr)
CO (1) CO4410203A1 (fr)
CZ (1) CZ287484B6 (fr)
DE (1) DE19521720B4 (fr)
DK (1) DK173015B1 (fr)
ES (1) ES2091727B1 (fr)
FI (1) FI118207B (fr)
FR (2) FR2721214B1 (fr)
GB (1) GB2291427B (fr)
GR (1) GR1003004B (fr)
HK (1) HK1015138A1 (fr)
HU (1) HU227240B1 (fr)
IE (1) IE68853B1 (fr)
IL (1) IL114151A (fr)
IT (1) IT1276723B1 (fr)
LU (1) LU88626A1 (fr)
MY (1) MY115631A (fr)
NL (1) NL1000566C2 (fr)
NO (1) NO322128B1 (fr)
NZ (1) NZ272359A (fr)
PE (1) PE19496A1 (fr)
PL (1) PL181310B1 (fr)
PT (1) PT101722B (fr)
RO (1) RO113530B1 (fr)
RS (1) RS49577B (fr)
RU (1) RU2152399C2 (fr)
SE (1) SE509052C2 (fr)
SI (1) SI9500200A (fr)
TW (1) TW421596B (fr)
UA (1) UA26874C2 (fr)
ZA (1) ZA954943B (fr)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
DE69630527T2 (de) * 1995-06-30 2004-08-05 Novo Nordisk A/S Vorbeugung einer krankheit mit diabetes charakter
RU2182015C2 (ru) * 1996-06-20 2002-05-10 Ново Нордиск А/С ПРЕПАРАТ ИНСУЛИНА, СОДЕРЖАЩИЙ NaCl, ПАРЕНТЕРАЛЬНАЯ ГОТОВАЯ ФОРМА, СПОСОБ ПОВЫШЕНИЯ ХИМИЧЕСКОЙ СТАБИЛЬНОСТИ ПРЕПАРАТА ИНСУЛИНА
AR012894A1 (es) * 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
IL134901A0 (en) 1997-10-24 2001-05-20 Lilly Co Eli Insoluble insulin compositions
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
KR20010080132A (ko) * 1998-10-16 2001-08-22 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 멘톨을 포함하는 폐 송달을 위한 인슐린 조제물
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
IL142011A0 (en) * 1998-10-16 2002-03-10 Novo Nordisk As Stable concentrated insulin preparations for pulmonary delivery
ATE259653T1 (de) * 1998-11-18 2004-03-15 Novo Nordisk As Stabile wässrige insulinzubereitungen ohne phenol und kresol
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
DK1383540T3 (da) * 2000-07-31 2009-08-24 Univ Bar Ilan Fremgangsmdåer og farmaceutiske sammensætninger til sårheling
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
EP1469827B1 (fr) 2002-01-09 2017-12-27 Emisphere Technologies, Inc. Polymorphes de 4- (4-chloro-2-hydroxybenzoyl)amino butanoate de sodium
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
US7547821B2 (en) 2003-06-17 2009-06-16 Sembiosys Genetics Inc. Methods for the production of insulin in plants
WO2005012346A1 (fr) * 2003-07-25 2005-02-10 Conjuchem, Inc. Derives de l'insuline longue duree et procedes associes
CA2553392A1 (fr) * 2004-01-16 2005-08-11 Biodel Inc Dispositif d'administration sublinguale de medicaments
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
CN102001963B (zh) 2004-05-06 2014-04-16 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
WO2005117854A2 (fr) * 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Composes d'aryle cetone et compositions pour la delivrance d'agents actifs
EP1750674A4 (fr) * 2004-05-27 2012-05-23 Advanced Bionutrition Corp Microparticules pour administration orale
US7872095B2 (en) 2004-07-19 2011-01-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US20100048454A1 (en) * 2004-08-03 2010-02-25 Emisphere Technologies, Inc. Antidiabetic oral insulin-biguanide combination
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
PT2918286T (pt) * 2004-10-05 2020-03-27 Novo Nordisk As Formulação farmacêutica
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
EP1862174A1 (fr) * 2005-03-02 2007-12-05 Ajinomoto Co., Inc. Inhibiteur de la formation d insuline polymere
NZ566083A (en) 2005-08-29 2012-11-30 Healor Ltd Methods and compositions for prevention and treatment of diabetic and aged skin
CN101627011A (zh) 2005-09-19 2010-01-13 爱密斯菲尔科技公司 N-(5-氯水杨酰基)-8-氨基辛酸的二钠盐的晶形
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
EP1991575A1 (fr) * 2006-02-21 2008-11-19 Novo Nordisk A/S Analogues d'insuline à chaîne unique et formules pharmaceutiques contenant lesdits analogues
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
AU2007238114B2 (en) 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2008043033A2 (fr) 2006-10-04 2008-04-10 Case Western Reserve University Insuline et analogues de l'insuline résistants à la fibrillation
CA2681158C (fr) 2007-03-13 2018-09-18 Nutrition 21, Inc. Procedes et compositions utilises pour la liberation prolongee de chrome
US8466199B2 (en) * 2007-03-21 2013-06-18 Emisphere Technologies, Inc. Allyloxy and alkyloxy benzoic acid delivery agents
EP2514412A1 (fr) * 2007-04-30 2012-10-24 Novo Nordisk A/S Solutions et compositions d'insuline fortement concentrée
WO2009002867A2 (fr) 2007-06-26 2008-12-31 Nutrition 21, Inc. Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
KR101234540B1 (ko) 2007-10-16 2013-02-19 바이오콘 리미티드 경구 투여가능한 고형 약제학적 조성물 및 그 제조방법
KR101344369B1 (ko) 2007-11-02 2013-12-24 에미스페어 테크놀로지스, 인코포레이티드 비타민 ｂ12 결핍 치료방법
MY158627A (en) 2008-07-31 2016-10-31 Univ Case Western Reserve Halogen-stabilized insulin
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
CA2750252A1 (fr) 2009-01-28 2010-08-05 Smartcells, Inc. Conjugues synthetiques et leurs utilisations
SG2014006597A (en) 2009-01-28 2014-04-28 Smartcells Inc Conjugate based systems for controlled drug delivery
CN102316892B (zh) 2009-02-12 2014-06-04 西马生物医学计划公司 心肌营养素-1用于治疗代谢病的用途
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
PT2498801T (pt) 2009-11-13 2018-05-02 Sanofi Aventis Deutschland Composição farmacêutica compreendendo despro36exendin-4(1-39)-lys6-nh2 e metionina
EP2536421A4 (fr) 2010-01-11 2013-10-09 Healor Ltd Procédé de traitement du psoriasis
AR080292A1 (es) * 2010-02-24 2012-03-28 Emisphere Tech Inc Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN107759771A (zh) 2010-09-30 2018-03-06 索尔维公司 天然来源的环氧氯丙烷的衍生物
WO2012115641A1 (fr) 2011-02-23 2012-08-30 Elona Biotechnologies Compositions de pro-insuline lis-pro et procédés de production d'analogues d'insuline lis-pro à partir de celles-ci
CA2828572C (fr) 2011-03-01 2021-02-23 Jds Therapeutics, Llc Compositions d'insuline et de chrome pour traitement et prevention du diabete, de l'hypoglycemie et de troubles associes
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
KR101983982B1 (ko) 2011-08-29 2019-05-30 사노피-아벤티스 도이칠란트 게엠베하 2형 당뇨병 환자의 혈당 조절에 사용하기 위한 약제학적 병용물
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
SG11201401835VA (en) 2011-10-27 2014-09-26 Univ Case Western Reserve Ultra-concentrated rapid-acting insulin analogue formulations
WO2014004278A1 (fr) * 2012-06-26 2014-01-03 The Curators Of The University Of Missouri Conjugués de médicament photoclivables
DK2877200T3 (da) 2012-07-17 2019-08-12 Univ Case Western Reserve O-bundne carbonhydratmodificerede insulinanaloger
EA034393B1 (ru) 2012-11-13 2020-02-03 Адосиа Состав инсулина быстрого действия, содержащий замещенное анионное соединение
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
BR112015011179A8 (pt) 2012-12-19 2019-10-01 Wockhardt Ltd composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
WO2014102623A1 (fr) 2012-12-26 2014-07-03 Wockhardt Limited Composition pharmaceutique
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
TW201605489A (zh) 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
WO2016032869A1 (fr) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Procédé de préparation de compositions d'analogue d'insuline ou d'insuline cristallines
NZ733670A (en) 2014-12-12 2021-12-24 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
EA201992351A1 (ru) 2017-06-01 2020-03-26 Эли Лилли Энд Компани Быстродействующие композиции инсулина
WO2019125878A1 (fr) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
WO2019125879A2 (fr) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Systèmes à base de conjugués pour l'administration contrôlée d'insuline
US11951186B2 (en) 2019-10-25 2024-04-09 Willow Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
AU2021247169A1 (en) 2020-03-31 2022-10-20 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
AU2021382599A1 (en) 2020-11-19 2023-06-22 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023225534A1 (fr) 2022-05-18 2023-11-23 Protomer Technologies Inc. Composés contenant du bore aromatiques et analogues d'insuline associés

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
PT93057B (pt) * 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
JP2837956B2 (ja) * 1993-06-21 1998-12-16 ノボ ノルディスク アクティーゼルスカブ Ａｓｐ▲上Ｂ２８▼インスリン結晶
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
FR2741078A1 (fr) 1997-05-16
PL309098A1 (en) 1995-12-27
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
BR9502795A (pt) 1996-03-12
YU39695A (sh) 1997-08-22
JP3171541B2 (ja) 2001-05-28
AT408720B (de) 2002-02-25
CA2151560C (fr) 2000-05-09
PT101722A (pt) 1995-12-29
DK173015B1 (da) 1999-11-15
GB2291427B (en) 1998-09-16
GB9512038D0 (en) 1995-08-09
NO952357D0 (no) 1995-06-14
LU88626A1 (fr) 1996-02-01
IL114151A0 (en) 1995-10-31
FI952931A0 (fi) 1995-06-14
HK1015138A1 (en) 1999-10-08
ATA101695A (de) 2001-07-15
CA2151560A1 (fr) 1995-12-17
RS49577B (sr) 2007-04-10
ITMI951278A1 (it) 1996-12-14
HUT73186A (en) 1996-06-28
UA26874C2 (uk) 1999-12-29
PT101722B (pt) 1997-02-28
PE19496A1 (es) 1996-06-01
FI952931A (fi) 1995-12-17
SE509052C2 (sv) 1998-11-30
FR2741078B1 (fr) 1998-08-07
ZA954943B (en) 1997-09-14
CO4410203A1 (es) 1997-01-09
JPH083067A (ja) 1996-01-09
PL181310B1 (pl) 2001-07-31
SI9500200A (en) 1996-02-29
KR100382326B1 (ko) 2003-07-07
CN1122248A (zh) 1996-05-15
NZ272359A (en) 1996-10-28
ES2091727A1 (es) 1996-11-01
JP2001199899A (ja) 2001-07-24
AU2168095A (en) 1996-01-04
US5474978A (en) 1995-12-12
IT1276723B1 (it) 1997-11-03
SE9502167L (sv) 1995-12-17
HU227240B1 (en) 2010-12-28
DK67795A (da) 1995-12-17
AU694501B2 (en) 1998-07-23
MY115631A (en) 2003-08-30
CZ154295A3 (en) 1996-02-14
CN1105576C (zh) 2003-04-16
GR950100229A (en) 1996-02-29
RO113530B1 (ro) 1998-08-28
RU95110109A (ru) 1997-05-10
IE68853B1 (en) 1996-07-24
HU9501716D0 (en) 1995-08-28
NL1000566A1 (nl) 1995-12-18
CH689935A5 (de) 2000-02-15
RU2152399C2 (ru) 2000-07-10
GR1003004B (el) 1998-11-05
DE19521720B4 (de) 2009-09-03
CH689250A5 (de) 1999-01-15
DE19521720A1 (de) 1995-12-21
ITMI951278A0 (it) 1995-06-14
FR2721214A1 (fr) 1995-12-22
SE9502167D0 (sv) 1995-06-14
CZ287484B6 (en) 2000-12-13
IE950436A1 (en) 1995-12-27
IL114151A (en) 2000-09-28
NO952357L (no) 1995-12-18
NL1000566C2 (nl) 1996-12-03
BE1009408A5 (fr) 1997-03-04
TW421596B (en) 2001-02-11
NO322128B1 (no) 2006-08-21
FI118207B (fi) 2007-08-31
KR960000924A (ko) 1996-01-25

Similar Documents

Publication Publication Date Title
FR2721214B1 (fr) Formulations d'analogues de l'insuline.
FR2721215B1 (fr) Formulations d'analogues monomères de l'insuline.
PT1283051E (pt) Formulacoes de insulina estaveis
ITRM940324A0 (it) "formulazioni galenione contenenti macrolidi".
EE03832B1 (et) Heptapeptiidanaloogid
OA09305A (en) "Pesticidal formulations".
SI0884053T1 (en) Stable insulin formulations
TR199501328A2 (tr) Alzheimer peptidi.
GB9402189D0 (en) Biologically active formulations
KR950016991U (ko) 이 강종 연연주용 치구
EG20349A (en) insecticidal n'-substituted-n,n-diacylhydrazines
GB2327424B (en) Monomeric insulin analog formulations
EG26644A (en) Preparations of monoclonal insulin analogs
ITEN940002V0 (it) G.s.50
IT1289617B1 (it) Diazinoni ad attivita' fungicida
KR950024858U (ko) 카리프트의 풋보드 확장장치
ITAQ960003A1 (it) Confetto "tartufo".
KR970009739U (ko) 투포원 연사기의 연사대를 이용하는 합연사 장치
ZA9810587B (en) Anaesthetic formulation.
SE9403120D0 (sv) Overall "Easy"